Second-line Treatment of Metastatic Colorectal Cancer
Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this multicenter, single-arm, observational cohort study is to investigate the efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab in colorectal cancer with prior oxaliplatin and fluoropyrimidine-based chemotherapy (including 5-FU/capecitabine/S-1) exposure in the metastatic setting or within 12 months of recurrence.
Phase:
PHASE2
Details
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborators:
Binzhou Medical University Binzhou People's Hospital Linyi Tumour Hospital Qianfoshan Hospital Shandong Provincial Hospital The Affiliated Hospital of Qingdao University Yantai Yuhuangding Hospital
Treatments:
Bevacizumab Irinotecan trifluridine tipiracil drug combination